Belite Bio (BLTE) Receivables - Accured (2025)
Belite Bio (BLTE) posted quarterly Receivables - Accured of $634000.0 for Q4 2025.
Powered by 
Analysis
Belite Bio (BLTE) Receivables - Accured (2025) Analysis & Trends
Belite Bio's Receivables - Accured history runs 1 years deep, the most recent figure standing at $634000.0 for Q4 2025.
- In Q4 2025, Receivables - Accured changed N/A year-over-year to $634000.0; the TTM figure through Dec 2025 stood at $634000.0 (changed N/A YoY), while the FY2025 annual figure was $634000.0, changed N/A from the prior year.
- Receivables - Accured for Q4 2025 stood at $634000.0.
- The five-year high for Receivables - Accured was $634000.0 in Q4 2025, with the low at $634000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 10 | Belite Bio | 6.25 Bn | 6.25 Bn | - | - |